Fairmount Funds Management LLC - Q4 2021 holdings

$303 Million is the total value of Fairmount Funds Management LLC's 20 reported holdings in Q4 2021. The portfolio turnover from Q3 2021 to Q4 2021 was - .

 Value Shares↓ Weighting
BHVN NewBIOHAVEN PHARMACTL HLDG CO$7,669,00055,647
+100.0%
2.53%
Original filings

The following EDGAR filing(s) were analyzed to create this report:

  • View 13F-HR filed 2022-02-14
Signatures

The EDGAR filing(s) were signed by:

Top long-term holdings
NameQuarters ownedLatest quarter ownedMax weighting
ARGENX SE16Q3 20239.3%
AXSOME THERAPEUTICS INC15Q3 202324.6%
INSMED INC12Q3 202215.0%
ACADIA PHARMACEUTICALS INC12Q3 202215.5%
IOVANCE BIOTHERAPEUTICS INC12Q3 20229.4%
COGENT BIOSCIENCES INC12Q3 20237.2%
ENANTA PHARMACEUTICALS INC12Q3 20229.6%
ALLAKOS INC12Q3 20227.4%
AMARIN CORP PLC12Q3 202210.9%
VERONA PHARMA PLC12Q2 202311.9%

View Fairmount Funds Management LLC's complete holdings history.

Latest significant ownerships (13-D/G)
Fairmount Funds Management LLC Q4 2021 significant holdings filed using form 13D/G when ownership exceeds 5% of a company's total stock issue.
FiledShares Percentage
Aeglea BioTherapeutics, Inc.June 30, 202317,230,54020.0%
Olema Pharmaceuticals, Inc.Sold outFebruary 14, 202300.0%
CATABASIS PHARMACEUTICALS INCJune 17, 20214,092,1665.3%
MIRAGEN THERAPEUTICS, INC.January 05, 2021967,67120.0%
Unum Therapeutics Inc.July 10, 20207,482,46020.0%

View Fairmount Funds Management LLC's complete significant-ownership history.

Latest filings
TypeFiled
42024-04-25
SC 13D/A2024-04-25
42024-04-01
42024-04-01
42024-04-01
42024-04-01
SC 13D/A2024-04-01
SC 13D/A2024-04-01
SC 13D/A2024-04-01
SC 13D/A2024-04-01

View Fairmount Funds Management LLC's complete filings history.

Compare quarters

Issues

The following issues were detected while analyzing the report:

  • The reported total value is incorrect (303333000.0 != 303335000.0)

Export Fairmount Funds Management LLC's holdings